Company has promoted Leesa Gentry to Chief
Clinical Officer and Ronald B. Kocak to Principal Accounting
Officer
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq:
RNXT), a clinical-stage biopharmaceutical company developing
novel precision oncology therapies based on a local drug-delivery
platform, today highlighted the recent key leadership promotions of
Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to
Principal Accounting Officer.
Shaun Bagai, Chief Executive Officer of RenovoRx, commented, “We
are delighted to promote Leesa and Ron to their new leadership
roles, which reflects our commitment to assembling a dynamic team
poised to continue to lead a successful clinical pathway for our
proprietary therapy platform. We have streamlined our team,
focusing our efforts on strategic initiatives to drive growth and
innovation. On behalf of our Board of Directors, I extend our
gratitude to Leesa and Ron on their hard work and dedication to
date and congratulate them on their well-deserved promotions.”
Ms. Gentry has served as Senior Vice President of Clinical
Operations at RenovoRx since April 2023. In her new role as Chief
Clinical Officer, she will oversee clinical and regulatory
operations ensuring the highest standards for safety and quality
are met across RenovoRx clinical studies. Ms. Gentry will continue
to implement her breadth of experience as the Company drives
towards a second interim analysis for the Phase III TIGeR-PaC study
evaluating RenovoRx’s lead product candidate, RenovoGemTM for the
treatment of Locally Advanced Pancreatic Cancer (LAPC), which is
expected by late 2024.
Since joining RenovoRx, Ms. Gentry has demonstrated exemplary
leadership and commitment to advancing the Company’s clinical
pipeline. In 2023, Ms. Gentry helped to achieve the first interim
analysis in the TIGeR-PaC with the Data Monitoring Committee
recommending a continuation of the study. The TIGeR-PaC study’s
primary endpoint is a 6-month Overall Survival benefit with
secondary endpoints including reduced side effects versus standard
of care. Under her guidance, the Company’s clinical strategy to
date has yielded positive results that contribute to the Company’s
commitment to improve patients’ lives and lifespans by delivering
therapies that have the potential to revolutionize the current
paradigm of cancer care.
Mr. Kocak has been promoted to the position of Principal
Accounting Officer and will retain his roles as Vice President and
Controller of RenovoRx. He joined the Company in October 2021 and
is a seasoned financial reporting and accounting professional with
extensive public and private company experience in the life
sciences industry. Mr. Kocak was instrumental in the recent
completion of a $6.1 million private placement that extended
RenovoRx’s cash runway to support its clinical program initiatives.
In this new leadership role, Mr. Kocak will oversee all financial
management, reporting and strategic planning initiatives crucial to
furthering the Company’s research and development efforts.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company
developing proprietary targeted combination therapies for high
unmet medical need with a goal to improve therapeutic outcomes for
cancer patients undergoing treatment. The Company’s proprietary
Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is
designed to ensure precise therapeutic delivery to directly target
the tumor while potentially minimizing a therapy’s toxicities
versus systemic (intravenous (IV) therapy). RenovoRx’s unique
approach to targeted treatment offers the potential for increased
safety, tolerance, and improved efficacy. Our Phase III lead
product candidate, RenovoGemTM, a novel oncology drug-device
combination product, is being investigated under a US IND that is
regulated by FDA 21 CFR 312 pathway. RenovoGem is currently being
evaluated for the treatment of locally advanced pancreatic cancer
(LAPC) by the Center for Drug Evaluation and Research (the drug
division of FDA.)
RenovoRx is committed to transforming the lives of patients by
delivering innovative solutions to change the current paradigm of
cancer care. RenovoGem is currently under investigation for TAMP
therapeutic delivery of gemcitabine and has not been approved for
commercial sale.
For more information, visit www.renovorx.com. Follow RenovoRx on
Facebook, LinkedIn, and Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and
Section 21E of the Securities Exchange Act of 1934, including but
not limited to statements regarding (i) the anticipated benefits of
the promotions of the Company’s executives as described herein and
(ii) our clinical trials and studies, including anticipated timing,
statements regarding the potential of RenovoCath®, RenovoGem™ or
TAMP™ or regarding our ongoing TIGeR-PaC Phase III clinical trial
study in LAPC, (iii) the potential for our product candidates to
treat or provide clinically meaningful outcomes for certain medical
conditions or diseases and (iv) our efforts to expand our
intellectual property. Statements that are not purely historical
are forward-looking statements. The forward-looking statements
contained herein are based upon our current expectations and
beliefs regarding future events, many of which, by their nature,
are inherently uncertain, outside of our control and involve
assumptions that may never materialize or may prove to be
incorrect. These may include estimates, projections and statements
relating to our research and development plans, intellectual
property development, clinical trials, our therapy platform,
business plans, financing plans, objectives and expected operating
results, which are based on current expectations and assumptions
that are subject to known and unknown risks and uncertainties that
may cause actual results to differ materially and adversely from
those expressed or implied by these forward-looking statements.
These statements may be identified using words such as “may,”
“expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,”
“estimates,” “intends,” and “potential,” or the negative of these
terms or other comparable terminology regarding RenovoRx’s
expectations strategy, plans or intentions, although not all
forward-looking statements contain these words. These
forward-looking statements are subject to a number of risks,
uncertainties and assumptions, that could cause actual events to
differ materially from those projected or indicated by such
statements, including, among other things: (i) the risk that the
recently promoted executives will be unable to fulfill their roles
as anticipated; (ii) circumstances which would adversely impact our
ability to efficiently utilize our cash resources on hand or raise
additional funding, (iii) the timing of the initiation, progress
and potential results (including the results of interim analyses)
of our preclinical studies, clinical trials and our research
programs; (iv) the possibility that interim results may not be
predictive of the outcome of our clinical trials, which may not
demonstrate sufficient safety and efficacy to support regulatory
approval of our product candidate, (v) that the applicable
regulatory authorities may disagree with our interpretation of the
data; research and clinical development plans and timelines, and
the regulatory process for our product candidates; (vi) future
potential regulatory milestones for our product candidates,
including those related to current and planned clinical studies;
(vii) our ability to use and expand our therapy platform to build a
pipeline of product candidates; (viii) our ability to advance
product candidates into, and successfully complete, clinical
trials; (ix) the timing or likelihood of regulatory filings and
approvals; (x) our estimates of the number of patients who suffer
from the diseases we are targeting and the number of patients that
may enroll in our clinical trials; (xi) the commercialization
potential of our product candidates, if approved; (xii) our ability
and the potential to successfully manufacture and supply our
product candidates for clinical trials and for commercial use, if
approved; (xiii) future strategic arrangements and/or
collaborations and the potential benefits of such arrangements;
(xiv) our estimates regarding expenses, future revenue, capital
requirements and needs for additional financing and our ability to
obtain additional capital; (xv) the sufficiency of our existing
cash and cash equivalents to fund our future operating expenses and
capital expenditure requirements; (xvi) our ability to retain the
continued service of our key personnel and to identify, and hire
and retain additional qualified personnel; (xvii) the
implementation of our strategic plans for our business and product
candidates; (xviii) the scope of protection we are able to
establish and maintain for intellectual property rights, including
our therapy platform, product candidates and research programs;
(xix) our ability to contract with third-party suppliers and
manufacturers and their ability to perform adequately; (xx) the
pricing, coverage and reimbursement of our product candidates, if
approved; and (xxi) developments relating to our competitors and
our industry, including competing product candidates and therapies.
Information regarding the foregoing and additional risks may be
found in the section entitled “Risk Factors” in documents that we
file from time to time with the Securities and Exchange
Commission.
Forward-looking statements included herein are made as of the
date hereof, and RenovoRx does not undertake any obligation to
update publicly such forward-looking statements to reflect
subsequent events or circumstances, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240308921763/en/
Investor Contact: KCSA Strategic Communications Valter
Pinto, Managing Director T: 212-896-1254 renovorx@kcsa.com
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
From Apr 2024 to May 2024
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
From May 2023 to May 2024